2. Perrigo

By Nesa Nourmohammadi

2011 generic drug sales: $620 million
Growth rate 2011: 80%
Growth rate 2010: 45%

From children's headaches to heartburn to hay fever, Perrigo pumps out meds for a wide variety of ailments. And it's the largest private-label, over-the-counter drug manufacturer in the U.S., cranking out 45 billion tablets a year.

While Allegan, MI-based Perrigo ($PRGO) may make a good chunk of dough from items such as infant formula and digestive supplements, its $540 million purchase of Paddock Laboratories last year reinforced its commitment to the generics market. The deal brought 35 new generic products into its portfolio, and was expected to contribute $200 million to sales during its first full year to Perrigo, CEO Joe Papa said at the time.

The journey hasn't been without its obstacles. In 2010, FDA issued a warning letter on its Allegan plant, citing several quality-control problems. One of them--ibuprofen tablets contaminated with metal shavings--resulted in a recall. Perrigo rebounded by remedying the issue within a year's time.

Looking ahead to the next 5 years, Perrigo sees branded prescription products worth $10 billion going OTC. That gives the company a chance to grab more sales in the allergy, heartburn, colds and disease-management markets.

2. Perrigo
Read more on

Suggested Articles

The FDA has handed down its decision against Sanofi and Lexicon's Zynquista.

Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.

The new Alcon shares will be listed on the Swiss Exchange and the New York Stock Exchange on April 9 under the ticker “ALC.”